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ABSTRACT: Jaundice in newborns provides a different response from the parents when 
compared to jaundice in older children and adults. Physiologic hyperbilirubinemia occurs 
commonly in term newborn infants in the absence of any underlying pathologic cause. Yet, 
the jaundice itself is commonly regarded as a problem in the transition to extrauterine life. 
In Neonatal hyperbilirubinemia (NHB) the total bilirubin level is greater than 15mg/dL in 
15 day or less old neonates and 2mg/dL in neonates above 15 days of age. Estimation of 
total bilirubin is preferred in the routine analyses for NHB compared to measurement of 
direct bilirubin. If certain conditions like sepsis, hepatic infections and other liver diseases 
are present it may be prudent to use direct bilirubin measurement. Yet contrary to the usual 
assumption of pathology, there are several lines of evidence supporting an adaptive role for 
neonatal hyperbilirubinemia. First, experimental and clinical evidence indicate that 
neonatal enzyme systems are not yet mature at birth; bilirubin has been demonstrated to 
scavenge potentially toxic oxygen free radicals that in later life are removed by the mature 
antioxidant enzyme system. Second, presence of bilirubin in mammals, similar patterns of 
expression of neonatal hyperbilirubinemia in nonhuman primates, and significant inter 
population variation in newborn serum bilirubin levels among humans all suggest that 
bilirubin production, metabolism, and excretion are under genetic control. Therefore 
bilirubin metabolism and its understanding may help improve its diagnosis and prognosis. 
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INTRODUCTION
ᴪ 
 
Neonatal hyperbilirubinemia (NHB), one of the 
most common problems pediatricians encounter in 
their clinical practice, remains a topic of interest 
and debate
1,2. 
Although the majority of neonatal jaundice is 
benign, a small number of hyperbilirubinemia 
poses a major health problem in term of bilirubin 
encephalopathy or kernicterus
3. Factors such as 
inadequate breast milk intake, imbalance between 
bilirubin production and conjugation and mutation 
of the gene encoding bilirubin conjugation have 
been identified to be associated with 
hyperbilirubinemia
4-6. Measurement of serum 
bilirubin in infants at risk and prompt intervention 
are the important steps in preventing 
hyperbilirubinemia and kernicterus. But identifying 
infants at risk and to obtain serum for bilirubin 
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estimation are still a cause for concern. The 
American Academy of Pediatrics (AAP) published 
a practice parameter on the management of 
hyperbilirubinemia in healthy term newborn in 
1994
7. These guidelines provide
  a framework for 
the prevention and management of 
hyperbilirubinemia
  in newborn infants of 35 or 
more weeks of gestation. In every
  infant, we 
recommend that clinicians - 1) promote and support
 
successful breastfeeding; 2) perform a systematic 
assessment
 before discharge for the risk of severe 
hyperbilirubinemia;
  3) provide early and focused 
follow-up based on the risk assessment;
  and 4) 
when indicated, treat newborns with phototherapy 
or exchange
 transfusion to prevent the development 
of severe hyperbilirubinemia
  and, possibly, 
bilirubin encephalopathy (kernicterus)
8,9. 
Resurgence of kernicterus, reported in the 
following years, partly questioned the adequacy of 
this parameter.). 
However, there were also comorbid factors, 
inappropiate application of the guidelines, lack of 
adherence and less concerned attitude that might Sheriff et al / Perspective on neonatal hyperbilirubinemia 
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play roles in it
3,8,9. In 2004, AAP issued a clinical 
practice guideline focused on reducing the 
frequency of severe hyperbilirubinemia and 
bilirubin encephalopathy
10. This review offers a 
perspective on neonatal jaundice by examining 
bilirubin metabolism, bilirubin neurotoxicity, the 
management of neonatal hyperbilirubinemia, and 
methods for the clinical assessment of neonatal 
jaundice. 
 
BILIRUBIN METABOLISM 
 
Bilirubin is the end product of heme degradation. 
The majority of bilirubin is derived from 
erythrocytes normally removed from the circulation 
and destroyed in the reticuloendothelial system. 
Heme oxygenase is the rate-limiting enzyme that 
catalyzes the alpha-specific oxidative cleavage of 
the heme molecule to form equimolar amounts of 
biliverdin and carbon monoxide. Biliverdin 
undergoes reduction via NADPH-dependent 
biliverdin reductase to form bilirubin. Bilirubin, 
after formation, is released into the circulation, 
where it is reversibly bound to albumin. Albumin 
in the circulation provides a vast bilirubin binding 
source, so that unbound bilirubin in plasma is 
generally low. Albumin transports bilirubin to its 
specific metabolic pathway in the liver, where 
bilirubin uptake is rapid. Intracellular transport of 
bilirubin from the hepatic plasma membrane to the 
endoplasmic reticulum, where conjugation occurs, 
is not well understood; however, cytosolic proteins 
(Y or ligandin Z or fatty-acid-binding protein) 
account for most of the intracellular bilirubin 
binding capacity. The conversion of bilirubin to 
mono- and di-glucuronide conjugates occurs in the 
endoplasmic reticulum.  A stepwise addition of D-
glucuronic acid from UDP-D-glucuronic acid to 
bilirubin, takes place with the help of the enzyme 
UDP-glucuronate-bilirubin glucuronyltransferase. 
The addition of glucuronide makes conjugated 
bilirubin water soluble and capable of canalicular 
transport into the bile. In the small bowel, bilirubin 
may be transiently deconjugated by bacterial and 
brush border enzymes before being further 
metabolized to other heme derived products. 
Because bilirubin P-glucuronidase is indigenous to 
the small bowel brush border, some bilirubin in the 
small bowel is deconjugated by this enzyme, 
reabsorbed at the brush border, and recirculated to 
the blood; this is known as the enterohepatic 
recirculation of bilirubin
11,12. 
Transient unconjugated hyperbilirubinemia 
develops in all newborns during the first week of 
life while they are adapting to the extrauterine 
environment. The interaction of several factors not 
present in adults contributes to this development, 
including a shorter mean red blood cell life span, a 
higher circulating red blood cell volume, a greater 
enterohepatic recirculation, and a hepatic system 
for uptake, enzymatic conjugation, and biliary 
excretion of bilirubin that is not yet fully 
functioning. 
 
TOXICITY OF UNCONJUGATED 
BILIRUBIN 
 
It is widely held, based on both laboratory 
investigations and epidemiologic studies, that 
unconjugated bilirubin is toxic to the central 
nervous system. “Kernicterus” was originally a 
term describing the typical autopsy findings of the 
brain in infants who died during severe jaundice, 
often caused by Rh isoimmunization or by 
infection. The term has also been used to identify 
the acute clinical, often fatal, condition in the 
severely jaundiced newborn characterized by 
convulsions, opisthotonos, hypotonia, high-pitched 
cry, and fever. Kernicterus has also been used to 
refer to the neurologic sequelae in survivors, 
including choreoathetosis, asymmetric spasticity, 
paresis of upward gaze, and neurogenic hearing 
loss
13-15. The term “bilirubin encephalopathy” is, in 
fact, more appropriate for the acute clinical 
findings. 
Hyperbilirubinemia in full-term infants has become 
an uncommon event in the last 30 years, as the 
result of the recognition of and early prenatal 
intervention in Rh-negative mothers and the 
widespread use of Rho (D) immune globulin 
(RhoGAM), exchange transfusions, and 
phototherapy.  After 1970, postmortem findings 
consistent with kernicterus were described in a new 
population of babies. With the improved survival of 
low-birth-weight (under 1500 grams) infants, 
pathologic changes were described even in the 
presence of low bilirubin levels and without the 
typical symptoms.
16,1 7 
Several clinical situations may increase the risk of 
bilirubin entry into and toxicity to the brain. These 
include concentration of unconjugated bilirubin 
high enough to exceed the bilirubin-binding 
capacity of albumin, due to severe hemolysis from 
Rh isoimmunization
18; bilirubin displacement from 
albumin by competing or affinity-altering 
molecules such as sulfisoxazole
19 or free fatty 
acids
20; and disruptions of the blood-brain barrier 
that allow bilirubin-protein complexes to enter the 
brain. In the newborn, the latter is most often 
caused by hypoxemia, hypercarbia, and 
hyperosmolar conditions
21,22. 
Clinical and experimental studies of bilirubin 
toxicity have provided mixed results and have not 
yielded a definitive model for the reactions that 
bilirubin undergoes after it enters the central 
nervous system or for the mechanism underlying its 
toxicity. 
In the newborn, the auditory pathway is vulnerable 
to damage from moderate to severe 
hyperbilirubinemia, resulting in sensorineural Sheriff et al / Perspective on neonatal hyperbilirubinemia 
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hearing loss
23. Birth weight less than 1500 grams, 
prolonged duration of hyperbilirubinemia, and 
acidotic episodes have been associated with 
sensorineural hearing loss. A direct correlation 
between increasing bilirubin concentration and 
changes in the amplitude and latency of auditory-
evoked brainstem potentials has been demonstrated 
in studies of infants
24,25. Acute changes in 
conduction time may be reversed by therapeutic 
intervention
26.  However, a well defined threshold 
for neurologic change has not been identified. In 
the healthy full-term infant, without hemolysis, 
detailed analyses, of a multitude of studies have 
failed to show any consistent effect of bilirubin 
(within a wide range of concentrations) on IQ, 
neurologic parameters, or hearing 
27. 
The current management of low-birth-weight 
infants, with prompt cardio respiratory stabilization 
and avoidance of drugs (including benzyl alcohol 
preservatives) believed to affect bilirubin 
metabolism and transport seems to have 
contributed to a decrease in the incidence of 
identifiable bilirubin toxicity
28. Unfortunately, the 
lack of detailed understanding of all the 
physiologic mechanisms accounting for bilirubin 
toxicity has prevented us from knowing when not 
to treat smaller infants for hyperbilirubinemia. 
Thus, early and aggressive use of phototherapy and 
occasional exchange transfusions remain part of 
routine care. 
 
THERAPY FOR NEONATAL 
HYPERBILIRUBINEMIA 
 
Phototherapy 
 
When bilirubin absorbs a photon of light, one of 
three possible photochemical reactions can occur: 
photo-oxidation, configurational isomerization, and 
structural isomerization.  Photo-oxidation results in 
the formation of colorless water-soluble molecules. 
Although originally thought to be the main 
pathway of bilirubin elimination during 
phototherapy, the reaction now appears to occur too 
slowly to be of clinical importance. Configurational 
isomerization is the conversion of the 4Z, 15Z-
bilirubin molecule to the 4Z, 15E-isomer a more 
water soluble form. Although formation of the Z, 
E-isomer is the most rapid of the photochemical 
reactions, this isomer is excreted slowly, if at all, in 
icteric infants. Structural isomerization produces 
lumirubin, a molecule that is formed relatively 
slowly but appears to be excreted fairly efficiently; 
it is thought to account for most or all of pigment 
elimination during phototherapy. Lumirubin has 
been identified as the major bilirubin species in 
urine and in aspirates of duodenal bile in infants 
undergoing phototherapy
29, 30. 
The color of light used in phototherapy is critical 
for its therapeutic success. As a yellow pigment, 
bilirubin can only absorb in the blue, violet, and 
green spectra. In vitro, 450 nm blue light is best 
absorbed; however, in vivo, light of longer 
wavelengths such as green light is thought to 
penetrate infant skin more deeply
28. 
Fluorescent daylight, blue light, and green light 
have been compared for efficacy in the 
management of non-hemolytic hyperbilirubinemia. 
The decrease in serum bilirubin concentration was 
fastest, and the required duration of phototherapy 
exposure was briefest, in the group of infants 
treated with blue light, which was twice as 
effective as green light
29-31. Recently, a controlled 
trial compared fiberoptic phototherapy with 
conventional phototherapy. Healthy newborns 
weighing less than 2500 grams with nonhemolytic 
hyperbilirubinemia were randomized either to wear 
a fiberoptic light source as a cummerbund around 
the torso or to receive phototherapy using standard 
equipment
32. Although fiberoptic phototherapy 
eliminated the need for eye protection and Isolette 
use and therefore promoted better infant-parent 
bonding, it was less effective than conventional 
phototherapy in decreasing serum bilirubin levels, 
presumably because of decreased irradiance. In 
general, phototherapy has no significant toxicity 
and its side effects are few (i.e. increased insensible 
water loss, diarrhea, skin rash, hypocalcemia, etc.) 
and are reversible with removal of the lights. 
 
Metalloporphyrins 
 
An alternative to treating neonatal 
hyperbilirubinemia by increasing bilirubin 
excretion, as in phototherapy, is to prevent the 
formation of bilirubin. Tin-protoporphyrin (Sn-PP) 
is a competitive inhibitor of heme oxygenase and 
thus can block the catabolism of heme and the 
production of bilirubin. In a study of SN-PP use in 
full-term newborns with Coombs-positive ABO 
incompatibility, infants who received a large dose 
of SN-PP (0.75 VL mol/kg per 24 hrs for 2-3 days) 
had lower serum bilirubin concentrations than 
control patients
31-33. Also, fewer patients in the SN-
PP treated group than in the control group required 
adjuvant phototherapy. From these data, it is 
unclear whether the primary effect of 
metalloporphyrin therapy is decreased bilirubin 
formation or increased photosensitivity of bilirubin 
resulting in increased excretion. Furthermore, the 
decrease in serum bilirubin concentration, although 
statistically significant was not clinically 
impressive. In addition, significant cutaneous side 
effects were noted including erythema and pruritis 
followed by edema and even tissue necrosis, 
thought to be a result of membrane damage from 
the formation of singlet oxygen. Other reported 
side effects include altered glutathione metabolism 
in the brain
34.  Additional potential effects, as yet 
unreported, include altered heme homeostasis, Sheriff et al / Perspective on neonatal hyperbilirubinemia 
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leading to changes in hemoproteins such as P450 
and thus to alterations in drug metabolism. At this 
time, caution in the use of SN-PP in the treatment 
of neonatal hyperbilirubinemia seems prudent until 
further data are available about its potentially toxic 
effects in the newborn
35,36. 
Pharmacologic agents used in the management of 
hyperbilirubinemia can accelerate bilirubin 
clearance via the normal metabolic pathways, 
inhibit the enterohepatic circulation of bilirubin or 
interfere with bilirubin formation by either 
blocking the degradation of heme or inhibiting 
hemolysis. Clofibrate as a hypolipidemic drug is a 
glucuronosyltransferase inducer which accelerates 
bilirubin elimination. In one of the studies 
Clofibrate is reported to be an effective adjunctive 
drug in neonatal hyperbilirubinemia, which results 
in decreased TSB level and reduced duration of 
phototherapy in late pre-term newborns.
37 
 
NONINVASIVE BILIRUBIN 
MEASUREMENT 
 
Although the major foci of research on neonatal 
jaundice have been toxicity and treatment, accurate 
and rapid measurement of elevated bilirubin 
concentration has also intrigued investigators. The 
standard clinical management of infants with 
jaundice includes visual estimation of extent and 
serial estimation of serum bilirubin
 concentration
35. 
Blood is obtained by repetitive venous, arterial, or 
capillary puncture. Any mode of obtaining blood is 
a source of discomfort and infection. 
Transcutaneous bilirubinometry is a noninvasive 
and cost-effective alternative. It is currently being 
investigated as a replacement for serum bilirubin 
testing or as a screening device to assess the need 
for serum bilirubin testing. 
 
VISUAL ESTIMATION OF BILIRIBIN 
 
Simple visual estimates for the presence or absence 
of jaundice are made daily by pediatricians to aid in 
the decision to test serum bilirubin levels. The 
visual estimate is refined by classifying the dermal 
zone of jaundice based on the phenomenon of 
cephalo-caudal progression. Jaundice in zone I 
(from head to neck and the level of the clavicle) 
translates approximately to a serum bilirubin 
concentration of 5 mg/dL; in zone 2 (from the 
clavicle to the umbilicus) to 6-8 mg/dL; in zone 3 
(from the umbilicus to the knees) to 9-12 mg/dL; in 
zone 4 (from the knees to the ankles) to 13-15 
mg/dL; and in zone 5 (the palms and soles) to over 
15 mg/dL. A second refinement of the visual 
estimate is the use of a “Tintometer” and “Ingram 
Icterometer” to gauge the depth of jaundice in 
newborns.
38,39 
 
 
TRANSCUTANEOUS ESTIMATES 
 
A more sophisticated device is the Minolta/Air 
Shields Jaundice Meter
38. It works via the principle 
of skin reflectance, which assumes that 
subcutaneous bilirubin is correlated in a linear 
fashion to serum bilirubin. The ability to estimate 
serum bilirubin values can be simplified by using 
the compartmental model
40. The relationship 
between the concentrations of bilirubin in the 
subcutaneous tissue compartment and the blood 
compartment is governed by rate constants that 
describe the rate of entry and exit of bilirubin from 
one compartment to another. To obtain a 
satisfactory correlation between these two values, 
the serum bilirubin and; the cutaneous bilirubin 
measurement must be accurate; and the two 
compartments and the kinetics of the transfer of 
bilirubin to and from each compartment must be 
similar for every infant
41. 
The first prerequisite, serum bilirubin measurement 
in the laboratory, is not met; inaccuracies cause a 
substantial degree of error in attempts to correlate 
transcutaneous and serum values. The accuracy of 
the second prerequisite, transcutaneous bilirubin 
measurement is equally problematic. In studies of 
the precision of jaundice meters, several 
investigators
42,43 have found them less precise for 
low serum bilirubin levels, but others
44,45 have 
suggested that the accuracy of the jaundice meter 
may be compromised at higher serum bilirubin 
concentrations. Accuracy may also be 
compromised by the variability of individual 
meters
43, the influence of operator technique 
41, and 
the presence of alcohol on the meter probe or the 
baby’s skin
41. The accuracy of jaundice meters is 
not only a function of precision, but also of the 
presence or absence of bias. It may be  in the form 
of additional or interfering race-dependent skin 
chromogenes and the presence of bruising or 
birthmarks
46-50. 
The third prerequisite for accurately correlating 
serum and subcutaneous bilirubin is that the two 
bilirubin compartments be stable in nature and that 
the kinetics of transfer between the two 
compartments be describable. Investigators who 
have examined this relationship between 
transcutaneous bilirubin values and serum bilirubin 
concentrations at various body sites generally have 
found the relationship to be linear and 
significant
31,42,51,52. However, factors such as 
exchange transfusions, phototherapy, body site of 
measurement, serum albumin concentration, pH, 
and gestational and chronological age have the 
potential to alter either the intrinsic nature of the 
serum bilirubin compartment or the kinetics 
governing the relationship of the two 
compartments. Thus, meeting this prerequisite is 
questionable. Sheriff et al / Perspective on neonatal hyperbilirubinemia 
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In homogeneous populations of full-term infants, 
investigators have found an excellent linear 
correlation between jaundice meters and serum 
bilirubin values, but in more heterogeneous 
populations and in non-steady-state conditions 
correlations are poor
44,53-55. Therefore, there is a 
doubt
40 that transcutaneous bilirubin values can 
routinely replace serum bilirubin concentrations in 
clinical practice. 
 
COMPUTERIZED PHOTOSENSOR 
 
To avoid some of the known problems with 
transcutaneous devices, we are in the midst of 
evaluating a computerized photosensor 
(Chromatics) that takes advantage of a wealth of 
information on skin tone available to the cosmetics 
industry. Instead of registering the simple change in 
skin color caused by bilirubin, the Chromatics 
meter can measure minute alterations in any one of 
a vast array of human skin types. This patient-
specific analysis takes account of race and skin 
perfusion and, in effect, allows the computer to 
“see bilirubin” below the surface. Some results
54 
suggest a degree of accuracy and linearity not 
available in other devices. Surprisingly, 
phototherapy does not seem to interfere with the 
measurement, even though infants, while being 
treated, appear less jaundiced to the eye. This 
suggests that the depth of measurement by this new 
device exceeds that which influences the visual 
assessment of skin color. 
The value of the Chromatics meter, or any other 
screening tool, ultimately rests on the clinician’s 
need to measure bilirubin in the newborn. The 
trends toward extremely early discharge after 
delivery, cost containment, and decreases in 
medical interventions should increase our 
requirements for simple and safe methods of 
determining which infants have more than just 
“physiologic” jaundice. If we couple this with a 
rational use of phototherapy, and newer treatments 
to eliminate hyperbilirubinemia, the incidence of 
significant hyperbilirubinemia may be reduced. In 
selected cases, such as severe, unexplained familial 
hyperbilirubinemia, it may be appropriate to refer a 
family for genetic counseling and to obtain 
genotype analysis of the UGT 1A1 gene, a test that 
is now available in some clinical laboratories.
58,59 
Prudent evaluation may facilitate prediction of 
severe jaundice and enable prevention of bilirubin 
encephalopathy in future siblings.
60 
 
 
 
CONCLUSION 
 
Notwithstanding a number of advances in the 
understanding of hyperbilirubinemia and its 
treatment in the newborn, controversy continues. 
The trend has been to decrease interventions and 
observe and manage infants with jaundice as 
outpatients. This trend will probably prove to be 
both medically and economically sound. In the 
absence of significant hemolysis or other 
underlying medical conditions such as infection, 
many physicians are now comfortable with 
expectant observation for those healthy full-term 
infants with serum bilirubin measurements of less 
than 18 mg/dL. New thinking about this condition 
and advances in treatment may transform 
hyperbilirubinemia in neonates into a medical 
curiosity. 
 
REFERENCES 
 
1.  Kaplan M, Hammerman C. Understanding and 
preventing severe neonatal hyperbilirubinemia: 
is bilirubin neurotoxicity really a concern in 
the developed world? Clin Perinatol. 
2004;31:555-7. 
2.  Hansen TWR. Kernicterus: an international 
perspective.  Semin Neonatol. 2002 
Apr;7(2):103-9. 
3.  Hansen TW. Bilirubin production, breast 
feeding and neonatal jaundice. Acta Paediatr. 
2001 Jul;90(7):716-23. 
4.  Kaplan M, Muraca M, Hammerman C, et al. 
Imbalance between production and conjugation 
of bilirubin: A fundamental concept in the 
mechanism of neonatal jaundice. Pediatrics. 
2002 Oct;110(4):e47. 
5.  Bancroft JD, Kreamer B, Gourley GR. Gilbert 
syndrome accelerates development of neonatal 
jaundice. J Pediatr. 1998 Apr;132(4):656-60. 
6.  American Academy of Pediatrics. Practice 
parameter: management of hyperbilirubinemia 
in the healthy term newborn. Pediatrics. 1994 
Oct;94(4 Pt 1):558-65. 
7.  Ip S, Lau J, Chung M, et al. 
Hyperbilirubinemia and kernicterus: 50 years 
later. Pediatrics. 2004 Jul;114(1):263-4. 
8.  Atkinson LR, Escobar GJ, Takayama JI, et al. 
Phototherapy use in jaundiced newborns in a 
large managed care organization: do clinician 
adhere to the guideline? Pediatrics. 2003 
May;111(5 Pt 1):e555-61. 
9.  American  Academy  of  Pediatrics 
Subcommittee  on  Hyperbilirubinemia. 
Management  of  hyperbilirubinemia  in  the 
newborn infant 35 or more weeks of gestation. 
Pediatrics. 2004 Jul;114(1):297-316. 
10.  Dennery PA, Seidman DS, Stevenson 
DK. Neonatal hyperbilirubinemia.  N  En gl  J 
Med. 2001 Feb;344(8):581-90. 
11.  Bhutani VK, Maisels MJ, Stark AR,et 
al. Management of jaundice and     prevention 
of severe neonatal hyperbilirubinemia in 
infants >or=35 weeks gestation. Neonatology. 
2008;94(1):63-7. Sheriff et al / Perspective on neonatal hyperbilirubinemia 
49 
Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved 
 
12.  Byers RK, Paine RS, Crothers B. 
Extrapyramidal cerebral palsy with hearing 
loss following erythroblastosis. Pediatrics. 
1955 Mar;15(3):248-54. 
13.  Sheriff DS, Ghwarsha K, Baxi AJ,et al. Serum 
vitamin E status in infants with neonatal 
hyperbilirubinemia.  Am J Obstet Gynecol. 
1986 Nov;155(5):1142-3. 
14.  Pearlstein MA. The late clinical syndrome of 
posticteric encephalopathy. Pediatr Clin 
North Am. 1960;7:665-87. 
15.  Gartner LM, Snyder RN, Chabon RS,et al. 
Kernicterus: high incidence in premature 
infants with low serum bilirubin 
concentrations.  Pediatrics. 1970 
Jun;45(5):906-17. 
16.  Kim MH, Yoon JJ, Sher J, et al. Lack of 
predictive indices in kernicterus: a comparison 
of clinical and pathologic factors in infants 
with or without kernicterus. Pediatrics 1980 
Dec;66(6):852-8. 
17.  Cashore WJ, Oh W. Unbound bilirubin and 
kernicterus in low-birth-weight infants. 
Pediatrics. 1982 Apr;69(4):481-5. 
18.  Bratlid D, Cashore WJ, Brubakk AM. 
Bilirubin displacement by sulfisoxasole: entry 
of unbound bilirubin into the rat brain. Pediatr 
Res. 1984 Apr;18(4):Al5O. 
19.  Brodersen R. Bilirubin transport in the 
newborn infant, reviewed with relation to 
kernicterus.  J Pediatr. 1980 Mar;96(3 Pt 
1):349-56. 
20.  Bratlid D, Cashore WJ, Oh W. Effect of 
acidosis on bilirubin deposition in rat brain. 
Pediatrics. 1984 Apr;73(4):431-4. 
21.  Bratlid D, Cashore WJ, Oh W. Effect of 
serum hyperosmolality on opening of blood-
brain barrier for bilirubin in rat brain. 
Pediatrics. 1983 Jun;71(6):909-12. 
22.  Cashore WJ. Kernicterus and bilirubin 
encephalopathy. Semin Liver Dis. 1988;8:163-
7. 
23.  de Vries LS, Lary S, Dubowitz LM. 
Relationship of senun bilirubin levels to 
ototoxicity and deafness in high risk low birth 
weight infants. Pediatrics. 1985 
Sep;76(3):351-4. 
24.  Nakamura H, Takada S, Shimabuku R, et al. 
Auditory nerve and brainstem responses in 
newborn infants with hyperbilirubinemia. 
Pediatrics. 1985 Apr;75(4):703-8. 
25.  Wennberg RP, Ahlfors CE, Bickers R, et al. 
Abnormal auditory brainstem response in a 
newborn with hyperbilirubinemia: 
improvement with exchange transfusion. J 
Pediatr. 1982 Apr;100(4):624-6. 
26.  Newman TB, Maisels MJ. Does 
hyperbilirubinemia damage the brain of 
healthy full-term infants? Clin Perinat. 1990 
Jan;17(2):331-58. 
27.  Scheidt PC, Graubard BI, Nelson KB, et al. 
Intelligence at six years in relation to neonatal 
bilirubin levels: follow-up of the National 
Institute of Child Health and Human 
Development Clinical Trial of Phototherapy. 
Pediatrics. 1991 Jun;87(6):797-805. 
28.  Ennever JF. Blue light, green light, white 
light, more light:treatment of neonatal 
jaundice.  Clin Perinat. 1990 Jun;17(2):467-
81. 
29.  Morris BH, Oh W, Tyson JE, et al Aggressive 
vs. conservative phototherapy for infants with 
extremely low birth weight. N Engl J Med. 
2008 Oct;359(18):1885-96. 
30.  Rastogi PK, Sreenivas V, Kumar N. 
Validation of CRIB II for prediction of 
mortality in premature babies. Indian 
Pediatrics. 2010 Feb;47(2):145-7. 
31.  Tan KL. Phototherapy for neonatal jaundice. 
Clin Perinat. 1991 Sep;18(3):423-39. 
32.  Holtrop PC, Madison K, Maisels MJ. Clinical 
trial of fiberoptic phototherapy vs. 
conventional phototherapy. Am J Dis Child. 
1992 Feb;146(2):235-7. 
33.  Kappas A, Drummond GS, Manola T, et al. 
Sn-protoporphyrin use in the management of 
hyperbilirubinemia in term newborns with 
direct Coombs-positive ABO incompatibility. 
Pediatrics. 1988 Apr;81(4):485-97. 
34.  McDonagh AF. Purple versus yellow: 
preventing neonatal jaundice with tin-
porphyrins. J Pediatr. 1988 Oct;1113(4):777-
81. 
35.  Stevenson DK, Rodgers PA, Vreman HJ. The 
use of metalloporphyrins for the 
chemoprevention of neonatal jaundice. Am J 
Dis Child. 1989;143:353-6. 
36.  Valaes TN, Harvey-Wilkes K. Pharmacologic 
approaches to the prevention and treatment of 
neonatal hyperbilirubinemia. Clin Perinatol. 
1990 Jun;17(2):245-73. 
37.  Sakha SH, Gharehbaghi MM, Rahbani ME. 
The effect of clofibrate with phototherapy in 
late pre-term newborns with non-hemolytic 
jaundice.  Indian J Med Sci. 2009 
May;63(5):174-9. 
38.  Rowntree LG, Brown GE. A tintometer for 
the analysis of the color of the skin. Am J Med 
Sci. 1925;170:341-5. 
39.  Gosset IH. A Perspex icterometer for 
neonates. Lancet. 1960 Jan;1(7115):87-8. 
40.  Freundlich JJ. Transcutaneous bilirubin 
measurement. J Clin Engineering. 1981 Oct-
Dec;6(4):307-11. 
41.  Rubatelli FF, Carli M. The effect of the light 
on the cutaneous bilirubin. Biol Neonate. 
1971;18(5):457-62. 
42.  Schumacher RE. Noninvasive measurements 
of bilirubin in the newborn. Clin Perinatol. 
1990 Jan;17(2):417-35. Sheriff et al / Perspective on neonatal hyperbilirubinemia 
50 
Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved 
 
43.  Kenney M, Metzger G, Landicho D, et al. 
Transcutaneous bilirubin monitoring of 
newborns. Ann N Y Acad Sci. 1984;428:251-5. 
44.  Yamanouchi 1, Yamauchi Y, Igarashi 1. 
Transcutaneous bilirubinometry: preliminary 
studies of noninvasive transcutaneous 
bilirubin meter in the Okayama National 
Hospital. Pediatrics. 1980 Feb;65(2):195-202. 
45.  Maisels MJ, Lee C. Transcutaneous bilirubin 
measurements: variation in meter response. 
Pediatrics. 1983 Mar;71(3):457-9. 
46.  Hegyi T, Hiatt IM, Indyk L. Transcutaneous 
bilirubinometry. I. Correlations in term 
infants. J Pediatr. 1981 Mar;98(3):454-7. 
47.  Bourchier D, Cull AF, Oettli PE. 
Transcutaneous bilirubinometry: 22 months 
experience at Waikato Women’s Hospital. N Z 
Med J. 1987 Sep;100(832):599-600. 
48.  Engel RR, Henis BB, Engel RE, et al. Effect 
of race and other variables on transcutaneous 
bilirubinometry. Pediatr Res. 1982;15:A543. 
49.  Goldman SL, Penalver A, Penaranda R. 
Jaundice meter: evaluation of new guidelines. 
J Pediatr. 1982 Aug;101(2):253-6. 
50.  Hannemann RE, Schreiner RL, DeWitt DP,et 
al. Evaluation of the Minolta bilirubin meter 
as a screening device in white and black 
infants. Pediatrics. 1982 Jan;69(1):107-9. 
51.  Tan KL. Transcutaneous bilirubinometry in 
full term Chinese and Malay infants. Acta 
Paediatr Scand. 1982 Jul;71(4):593-6. 
52.  Palmer DC, Zenner EM, Drew JH. 
Transcutaneous bitirubinometry: use in 
Australia. Aust Paediatr J. 1982;18:273-6. 
53.  Tudehope DI, Chang A. Multiple site readings 
from a transcutaneous bilirubinometer. Aust 
Paediatr J. 1982 Dec;18(4):102-5. 
54.  Maisels MJ, Corad S. Transcutaneous 
bilirubin measurements in full-term infants. 
Pediatrics. 1982 Sep;70(3);464-7. 
55.  Schumacher RE, Thornbery JM, Gutcher GR. 
Transcutaneous bilirubinometry: a comparison 
of old and new methods. Pediatrics. 1985 
Jul;76(1):10-14. 
56.  Yamauchi Y, Yamanouchi I. Transcutaneous 
bilirubinometry. Evaluation of accuracy and 
reliability in a large population. Acta Paediatr 
Scand. 1988 Nov;77(6):791-5. 
57.  Tayaba R, Gribetz D, Gribetz I, et al. A new 
computer-driven skin bilirubinometer: 
preliminary evaluation. Pediatr Res. 
1993;33:A239. 
58.  Kaplan M, Hammerman C, Maisels MJ. 
Bilirubin genetics for the nongeneticist: 
hereditary defects of neonatal bilirubin 
conjugation.  Pediatrics. 2003 Apr;111(4 pt 
1):886-93. 
59.  Zhou YY, Lee LY, Ng  SY, et al. UGT1A1 
haplotype mutation among Asians in 
Singapore Neonatology. 2009;96(3):150-5. 
60.  Bhutani VK, Johnson L. A proposal to prevent 
severe neonatal hyperbilirubinemia and 
kernicterus.  J Perinatol. 2009 Feb;29 Suppl 
1:S61-S67. 
 